222 related articles for article (PubMed ID: 34568975)
41. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
Reck M; Luft A; Szczesna A; Havel L; Kim SW; Akerley W; Pietanza MC; Wu YL; Zielinski C; Thomas M; Felip E; Gold K; Horn L; Aerts J; Nakagawa K; Lorigan P; Pieters A; Kong Sanchez T; Fairchild J; Spigel D
J Clin Oncol; 2016 Nov; 34(31):3740-3748. PubMed ID: 27458307
[TBL] [Abstract][Full Text] [Related]
42. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
[TBL] [Abstract][Full Text] [Related]
43. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy.
Kutlu Y; Aydin SG; Bilici A; Oven BB; Olmez OF; Acikgoz O; Hamdard J
Medicine (Baltimore); 2023 Apr; 102(15):e33432. PubMed ID: 37058061
[TBL] [Abstract][Full Text] [Related]
44. SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
Rudin CM; Liu SV; Soo RA; Lu S; Hong MH; Lee JS; Bryl M; Dumoulin DW; Rittmeyer A; Chiu CH; Ozyilkan O; Johnson M; Navarro A; Novello S; Ozawa Y; Tam SH; Patil NS; Wen X; Huang M; Hoang T; Meng R; Reck M
J Clin Oncol; 2024 Jan; 42(3):324-335. PubMed ID: 37976444
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of carboplatin and etoposide in older extensive-stage small-cell lung cancer patients with a poor performance status.
Mamesaya N; Kodama H; Iida Y; Kobayashi H; Ko R; Wakuda K; Ono A; Kenmotsu H; Naito T; Murakami H; Shimizu T; Gon Y; Takahashi T
Thorac Cancer; 2023 Mar; 14(9):805-814. PubMed ID: 36700290
[TBL] [Abstract][Full Text] [Related]
46. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group.
Gürbüz M; Kutlu Y; Akkuş E; Köksoy EB; Köse N; Öven BB; Uluç BO; Demiray AG; Erdem D; Demir B; Turhal NS; Üskent N; Akbaş S; Selçukbiricik F; İnal A; Bilici A; Ölmez ÖF; Çabuk D; Ünal Ç; Hızal M; Şendur MAN; Korkmaz M; Karadurmuş N; Ertürk İ; Göksu SS; Tatlı AM; Güven DC; Kılıçkap S; Paksoy N; Aydıner A; Çınkır HY; Özkul Ö; Öztürk A; Ballı S; Kemal Y; Erdoğan AP; Er Ö; Yumuk PF; Demirkazık A
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3547-3555. PubMed ID: 35689097
[TBL] [Abstract][Full Text] [Related]
47. A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.
Salgia R; Stille JR; Weaver RW; McCleod M; Hamid O; Polzer J; Roberson S; Flynt A; Spigel DR
Lung Cancer; 2017 Mar; 105():7-13. PubMed ID: 28236984
[TBL] [Abstract][Full Text] [Related]
48. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.
Cheng Y; Han L; Wu L; Chen J; Sun H; Wen G; Ji Y; Dvorkin M; Shi J; Pan Z; Shi J; Wang X; Bai Y; Melkadze T; Pan Y; Min X; Viguro M; Li X; Zhao Y; Yang J; Makharadze T; Arkania E; Kang W; Wang Q; Zhu J;
JAMA; 2022 Sep; 328(12):1223-1232. PubMed ID: 36166026
[TBL] [Abstract][Full Text] [Related]
49. Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.
Zhou K; Zhou J; Huang J; Zhang N; Bai L; Yang Y; Li Q
Lung Cancer; 2019 Apr; 130():1-4. PubMed ID: 30885327
[TBL] [Abstract][Full Text] [Related]
50. Prognostic implications of neutrophil-to-lymphocyte ratio in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy: A multicenter, real-world study.
Bi H; Ren D; Xiao Y; Zhou Y; Yi B; Han W; Shao Y; Wang J; Zhang C; Wang H
Thorac Cancer; 2024 Mar; 15(7):559-569. PubMed ID: 38294282
[TBL] [Abstract][Full Text] [Related]
51. Tumor mutational burden adjusted by neutrophil-to-lymphocyte ratio serves as a potential biomarker for atezolizumab-treated patients with extensive stage small cell lung cancer.
Zhang C; Huo Y; Shang X; Zhang T; Tang N; Wang H
Respir Res; 2024 Jun; 25(1):253. PubMed ID: 38902698
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.
Qu J; Kalyani FS; Shen Q; Yang G; Cheng T; Liu L; Zhou J; Zhou J
J Oncol; 2022; 2022():3645489. PubMed ID: 36199793
[TBL] [Abstract][Full Text] [Related]
53. Tolerability and efficacy of IMpower133 regimen modified for dialysis patients with extensive-stage small cell lung cancer: Two case reports.
Watari N; Yamaguchi K; Masuda T; Ito N; Sakamoto S; Horimasu Y; Miyamoto S; Nakashima T; Iwamoto H; Fujitaka K; Hamada H; Hattori N
Thorac Cancer; 2021 Nov; 12(21):2956-2960. PubMed ID: 34587368
[TBL] [Abstract][Full Text] [Related]
54. Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials.
Socinski MA; Jotte RM; Cappuzzo F; Nishio M; Mok TSK; Reck M; Finley GG; Kaul MD; Yu W; Paranthaman N; Bara I; West HJ
JAMA Oncol; 2023 Apr; 9(4):527-535. PubMed ID: 36795388
[TBL] [Abstract][Full Text] [Related]
55. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.
Spigel DR; Townley PM; Waterhouse DM; Fang L; Adiguzel I; Huang JE; Karlin DA; Faoro L; Scappaticci FA; Socinski MA
J Clin Oncol; 2011 Jun; 29(16):2215-22. PubMed ID: 21502556
[TBL] [Abstract][Full Text] [Related]
56. Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.
Wasamoto S; Imai H; Tsuda T; Nagai Y; Minemura H; Yamada Y; Umeda Y; Kishikawa T; Shiono A; Kozu Y; Shiihara J; Yamaguchi O; Mouri A; Kaira K; Kanazawa K; Taniguchi H; Kaburagi T; Minato K; Kagamu H
Front Oncol; 2022; 12():1080729. PubMed ID: 36741711
[TBL] [Abstract][Full Text] [Related]
57. FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010.
Debieuvre D; Dayen C; Dixmier A; Pau D; Sibley-Revelat A; Greenwood W; Gally S; Falchero L
Lung Cancer; 2022 Feb; 164():1-7. PubMed ID: 34954472
[TBL] [Abstract][Full Text] [Related]
58. Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer.
Tsuda T; Imai H; Nagai Y; Umeda Y; Shiono A; Shiihara J; Yamaguchi O; Mouri A; Kaira K; Ishizuka T; Taniguchi H; Kagamu H
Oncol Lett; 2023 Mar; 25(3):111. PubMed ID: 36817046
[TBL] [Abstract][Full Text] [Related]
59. Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study.
Byers LA; Bentsion D; Gans S; Penkov K; Son C; Sibille A; Owonikoko TK; Groen HJM; Gay CM; Fujimoto J; de Groot P; Dunbar M; Kang K; He L; Sehgal V; Glasgow J; Bach BA; Ellis PM
Clin Cancer Res; 2021 Jul; 27(14):3884-3895. PubMed ID: 33947690
[TBL] [Abstract][Full Text] [Related]
60. Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide.
Imai H; Mori K; Watase N; Fujimoto S; Kaira K; Yamada M; Minato K
Can Respir J; 2016; 2016():5405810. PubMed ID: 27445549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
